MedTrace Logo

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

NCT03554408 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2021-08-04

No results posted yet for this study

Summary

This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

10-1074-LS

Subcutaneous injection of 10-1074-LS

DRUG

10-1074-LS

Intravenous infusion of 10-1074-LS

DRUG

3BNC117-LS

Subcutaneous injection of 3BNC117-LS

DRUG

3BNC117-LS

Intravenous infusion of 3BNC117-LS

Sponsors & Collaborators

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Marina Caskey, MD · The Rockefeller University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-20
Primary Completion
2021-02-04
Completion
2021-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03554408 on ClinicalTrials.gov